François Meyer

François Meyer

Auto-generated profile, based on publicly available information

François Meyer

Department of Urology, Hôpital Saint-Louis, AP-HP, Paris, France; Department of Urology, Hôpital Privé des Peupliers, groupe Ramsay, Paris, France

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 December 2021 in Progrès en Urologie
Verified
Journal Article
Closed access
LEL. Even
L. Even
BTB. Tibi
B. Tibi
IBI. Bentellis
I. Bentellis
PTPatrick Treacy
Patrick Treacy
NBN. Berrogain
N. Berrogain
JCJ.N. Cornu
J.N. Cornu

19 November 2025 in The French Journal of Urology
Verified
Journal Article
Closed access
BPBenoit Peyronnet
Benoit Peyronnet
JKJulia Klap
Julia Klap
CBCaroline A. Brandon
Caroline A. Brandon
PBPierre-Olivier Bosset
Pierre-Olivier Bosset
SCSandrine Campagne-Loiseau
Sandrine Campagne-Loiseau
CTCaroline Thuillier
Caroline Thuillier

19 November 2025 in Progrès en Urologie - FMC
Verified
Journal Article
Closed access
BPB. Peyronnet
B. Peyronnet
JKJ. Klap
J. Klap
CBC.A. Brandon
C.A. Brandon
PBP.-O. Bosset
P.-O. Bosset
SCS. Campagne-Loiseau
S. Campagne-Loiseau
CTC. Thuillier
C. Thuillier

17 September 2025 in The French Journal of Urology
Verified
Journal Article
Closed access
CSChristian Saussine
Christian Saussine
XGXavier Gamé
Xavier Gamé
ALAmelie Levesque
Amelie Levesque
ECEmmanuel Chartier-Kastler
Emmanuel Chartier-Kastler
FMFrançois Meyer
François Meyer
CWConstanze Waltenberger
Constanze Waltenberger

6 March 2025 in Neurourology and Urodynamics
Verified
Journal Article
Open access
FMFrancois Meyer
Francois Meyer
JCJuliette Cotte
Juliette Cotte
LBLucas Bento
Lucas Bento
GNGuillaume Nicaud
Guillaume Nicaud
HWHubert Werth
Hubert Werth
BPBenoît Peyronnet
Benoît Peyronnet
Introduction: The reoperation rate for artificial urinary sphincters (AUS) in men is about 25%, with poorer survival rates when reimplantation occurs after urethral erosion or infection. Data on the outcomes of second AUS implants are rare, and no data exist for third AUS implants. We aimed to evaluate the functional and survival outcomes of a third AUS after two previous explantations.Methods: The records of all patients implanted with a third AUS between 2006 and 2023 in seven French university hospitals were reviewed retrospectively. Only AUS implants following two previous AUS cuff explantations or revisions were included. The primary endpoint was the reoperation‐free survival of the third AUS. Secondary endpoints included functional outcomes at 6 months and at the last follow‐up, and overall functional outcomes after possible subsequent AUS implants, as well as reoperations.Results: A total of 75 patients were included. Early complications occurred in 16.7% of patients. Median follow‐up was 11 months (1–122), 28 explantations were required (37.3%). The 5‐year reoperation‐free survival rate was 34.8%. The only significant predictive factor for explantation was smoking. At 6 months, 66.2% of patients were socially continent (0–1 protection per day), 10.8% were improved, and 23% were unchanged or worsened. At the last follow‐up of the third AUS, these results were 40%, 5.3%, and 54.7%, respectively. However, at the last overall follow‐up (median 12 months, 1–183), social continence was 54.8%, improvement 9.6%, and failure 35.6%, with 23 patients (30.7%) receiving a fourth or fifth AUS.Conclusion: Early functional outcomes of a third AUS are similar to primary AUS, but survival rates and late functional outcomes are inferior. Predictive factors for outcomes were related to patients, not the surgery itself. A third AUS may be suitable for motivated patients with limited therapeutic options. Further studies are needed to refine patient selection and assess the impact of reimplantation techniques on outcomes.

30 March 2026 in The French Journal of Urology
Verified
Journal Article
Open access
AGAlexandre Gac
Alexandre Gac
MPMaxime Pattou
Maxime Pattou
JGJérémie Gallon
Jérémie Gallon
FMFrançois Meyer
François Meyer
APArthur Peyrottes
Arthur Peyrottes
AMAlexandra Masson-Lecomte
Alexandra Masson-Lecomte
The objective of the study was to compare short-term functional outcomes and quality of life (QoL) between robot-assisted simple prostatectomy (RASP) and holmium laser enucleation of the prostate (HoLEP) in patients undergoing surgery for medium and large-volume benign prostatic hyperplasia (BPH) in our centre. In this retrospective study based on a prospectively maintained database, we included all consecutive patients treated with RASP or HoLEP at our centre between September 2021 and November 2023. Standardized questionnaires were administered preoperatively and at 6 and 20weeks postoperatively: IPSS with QoL item, Urinary Symptom Profile (USP) which includes stress urinary incontinence (SUI), overactive bladder (OAB) and dysuria assessment, as well as IIEF-5 score. Among 161 patients who underwent surgery (144 HoLEP, 17 RASP), only 71 (44%) completed all questionnaires (56 HoLEP, 15 RASP). This study focuses on these 71 patients. Except for prostate volume, which was higher in the RASP group (159mL vs 85.5mL, P<0.01), baseline characteristics and functional scores were comparable. At 20weeks, median IPSS scores were similar (5 vs 2, P=0.57), but median QoL scores favoured RASP (0 vs 1, P=0.04). RASP was associated with lower stress incontinence at both 6 and 20weeks (USP SUI scores 4 vs 0, P=0.01 and 2 vs 0, P=0.01, respectively), and less overactive bladder at 6weeks (USP OAB at 6weeks 10 vs 7, P=0.04). Postoperative IIEF-5 scores and maximal urinary flow rates were not significantly different between groups. Despite significant methodological limitations (selection and attrition biases, small sample size, and severe imbalance between groups), RASP may be associated with better early outcomes, particularly regarding continence and overactive bladder symptoms. These findings are limited by a questionnaire completion rate of 44% and a 20-week follow-up.